Company News
Palisade Bio Stock Up 14% FDA Clearance
FDA cleared Palisade Bio’s IND for PALI-2108, permitting launch of the global Phase 2 ASCENTRA‑UC trial in ulcerative colitis.
The trial will enroll about 204 patients across North America and Europe,
